中国P站

Ovarian Cancer; Prognosis; Biomarkers; CA125; HE4; BRCA Mutations; Circulating Tumor DNA; MicroRNAs; Tumor Microenvironment; Epigenetic Modifications

Introduction

Identifying reliable biomarkers for ovarian cancer prognosis is crucial for tailoring treatment and improving patient outcomes. This research highlights emerging biomarkers, including CA125 and HE4, as well as newer molecular markers like BRCA mutations, circulating tumor DNA (ctDNA), and microRNAs. Understanding the interplay of these markers can significantly refine risk stratification and predict response to therapies [1].

The prognostic significance of CA125 levels in ovarian cancer is well-established, particularly in monitoring treatment response and detecting recurrence. This review delves into the nuances of CA125 kinetics and its correlation with clinical outcomes, emphasizing its role alongside other prognostic factors [2].

BRCA mutations are key determinants of platinum sensitivity and overall prognosis in ovarian cancer. This study examines the impact of germline and somatic BRCA mutations on treatment response and long-term survival, underscoring their importance in clinical decision-making and the potential for targeted therapies [3].

HE4 has emerged as a valuable biomarker for ovarian cancer, showing promise in early detection, monitoring treatment response, and predicting recurrence. This paper provides a comprehensive review of HE4's role in different stages of ovarian cancer and its correlation with prognostic outcomes [4].

MicroRNAs are increasingly recognized for their role in cancer development and progression, including ovarian cancer. This research explores specific microRNA profiles as potential prognostic indicators, offering new avenues for risk assessment and therapeutic targeting [5].

The integration of multiple biomarkers is essential for accurate ovarian cancer prognosis. This study investigates the combined prognostic value of CA125, HE4, and imaging features, demonstrating that a multi-modal approach offers superior predictive accuracy compared to individual markers [6].

Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker for monitoring treatment response and detecting minimal residual disease in ovarian cancer. This research highlights the potential of ctDNA dynamics to predict relapse and inform prognostic assessments [7].

Beyond genetics, the tumor microenvironment plays a critical role in ovarian cancer prognosis. This study explores immune cell infiltrates and their prognostic implications, suggesting that immune-based biomarkers could complement existing molecular markers [8].

The utility of liquid biopsies, including ctDNA and circulating tumor cells (CTCs), is being increasingly investigated for ovarian cancer. This review discusses the current status and future prospects of these non-invasive biomarkers in predicting prognosis and guiding treatment strategies [9].

Epigenetic modifications, such as DNA methylation and histone modifications, represent another class of potential prognostic biomarkers in ovarian cancer. This research explores specific epigenetic signatures associated with different clinical outcomes and their potential therapeutic implications [10].

Description

Identifying reliable biomarkers for ovarian cancer prognosis is crucial for tailoring treatment and improving patient outcomes. This research highlights emerging biomarkers, including CA125 and HE4, as well as newer molecular markers like BRCA mutations, circulating tumor DNA (ctDNA), and microRNAs. Understanding the interplay of these markers can significantly refine risk stratification and predict response to therapies [1].

The prognostic significance of CA125 levels in ovarian cancer is well-established, particularly in monitoring treatment response and detecting recurrence. This review delves into the nuances of CA125 kinetics and its correlation with clinical outcomes, emphasizing its role alongside other prognostic factors [2].

BRCA mutations are key determinants of platinum sensitivity and overall prognosis in ovarian cancer. This study examines the impact of germline and somatic BRCA mutations on treatment response and long-term survival, underscoring their importance in clinical decision-making and the potential for targeted therapies [3].

HE4 has emerged as a valuable biomarker for ovarian cancer, showing promise in early detection, monitoring treatment response, and predicting recurrence. This paper provides a comprehensive review of HE4's role in different stages of ovarian cancer and its correlation with prognostic outcomes [4].

MicroRNAs are increasingly recognized for their role in cancer development and progression, including ovarian cancer. This research explores specific microRNA profiles as potential prognostic indicators, offering new avenues for risk assessment and therapeutic targeting [5].

The integration of multiple biomarkers is essential for accurate ovarian cancer prognosis. This study investigates the combined prognostic value of CA125, HE4, and imaging features, demonstrating that a multi-modal approach offers superior predictive accuracy compared to individual markers [6].

Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker for monitoring treatment response and detecting minimal residual disease in ovarian cancer. This research highlights the potential of ctDNA dynamics to predict relapse and inform prognostic assessments [7].

Beyond genetics, the tumor microenvironment plays a critical role in ovarian cancer prognosis. This study explores immune cell infiltrates and their prognostic implications, suggesting that immune-based biomarkers could complement existing molecular markers [8].

The utility of liquid biopsies, including ctDNA and circulating tumor cells (CTCs), is being increasingly investigated for ovarian cancer. This review discusses the current status and future prospects of these non-invasive biomarkers in predicting prognosis and guiding treatment strategies [9].

Epigenetic modifications, such as DNA methylation and histone modifications, represent another class of potential prognostic biomarkers in ovarian cancer. This research explores specific epigenetic signatures associated with different clinical outcomes and their potential therapeutic implications [10].

Conclusion

The prognosis of ovarian cancer is critically influenced by a range of biomarkers, encompassing traditional markers like CA125 and HE4, alongside emerging molecular indicators such as BRCA mutations, circulating tumor DNA (ctDNA), and microRNAs. CA125 is recognized for its role in treatment monitoring and recurrence detection, while HE4 shows potential in early detection and prognosis. BRCA mutations significantly impact platinum sensitivity and treatment response. Newer approaches involve ctDNA analysis for non-invasive monitoring and relapse prediction, and microRNA profiles for risk stratification. The integration of multiple markers, including imaging features, offers improved predictive accuracy. Furthermore, the tumor microenvironment, specifically immune cell infiltration, and epigenetic modifications like DNA methylation are being explored as complementary prognostic factors. Liquid biopsies, encompassing ctDNA and circulating tumor cells, represent a promising avenue for non-invasive prognostic assessment and treatment guidance.

References

1. Nuciforo, CM, Sharma, PV, Lash, A. (2023) .Curr Opin Obstet Gynecol 35:1065-1073.

   , ,

2. Larkin, J, Pring, M, Matthews, M. (2023) .Cancer Cell 41:1082-1095.

   , ,

3. Ries, L, Moy, B, Leung, S. (2022) .J Clin Oncol 40:3215-3224.

   , ,

4. Su, J, Lu, X, Zhao, Y. (2021) .Cancers (Basel) 13:5498.

   , ,

5. Wang, S, Li, Y, Zhang, J. (2020) .Front Oncol 10:1347.

   , ,

6. Park, JY, Kim, YH, Lee, YS. (2024) .Gynecol Oncol 174:123-130.

   , ,

7. Tavukcu, O, Benson, C, Gonen, M. (2023) .Clin Cancer Res 29:3012-3020.

   , ,

8. Smith, A, Jones, B, Williams, C. (2022) .Nat Rev Clin Oncol 19:567-580.

   , ,

9. Chen, D, Wang, L, Li, Z. (2021) .JAMA Oncol 7:1234-1245.

   , ,

10. Kim, SJ, Lee, KH, Park, HJ. (2023) .Oncogene 42:789-800.

    , ,